Article
Dermatology
Soie Kwon, Jeong Hyun Ha, Dong Ki Kim, Yon Su Kim, Chun Soo Lim, Hak Chang, Jung Pyo Lee, Ji-Ung Park
Summary: This study examined the effect of metformin on diabetic foot ulcer in a large diabetic kidney disease cohort. The results showed that metformin users had a lower incidence and severity of diabetic foot ulcer events.
INTERNATIONAL WOUND JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Yuan Lin, Te-Hsiung Wang, Ming-Lung Tsai, Victor Chien-Chia Wu, Chin-Ju Tseng, Ming-Shyan Lin, Yan-Rong Li, Chih-Hsiang Chang, Tien-Shin Chou, Tzu-Hsien Tsai, Ning- Yang, Ming-Jui Hung, Tien-Hsing Chen
Summary: GLP-1 receptor agonists have a neutral effect on cardiovascular outcomes but reduce kidney events in patients with advanced diabetic kidney disease compared with DPP-4 inhibitors.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Immunology
Suyan Duan, Lianqin Sun, Chengning Zhang, Lin Wu, Guangyan Nie, Zhimin Huang, Changying Xing, Bo Zhang, Yanggang Yuan
Summary: The platelet-to-lymphocyte ratio (PLR) is associated with proteinuria and prognosis in diabetic kidney disease (DKD) patients, and serves as an independent risk factor for kidney progression in biopsy-proven DKD.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Urology & Nephrology
Frank C. Brosius, David Cherney, Patrick O. Gee, Raymond C. Harris, Alan S. Kliger, Katherine R. Tuttle, Susan E. Quaggin
Summary: Diabetes and its complications pose a severe threat to humankind, with diabetic kidney disease being one of the most devastating complications. Current treatment methods for diabetic kidney disease are limited, presenting challenges for both patients and healthcare providers. Recent advancements in therapies promise to transform care for patients with diabetes and kidney disease.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Christodoula Kourtidou, Maria Stangou, Smaragdi Marinaki, Konstantinos Tziomalos
Summary: This review summarizes the current knowledge on emerging cardiovascular risk markers in patients with diabetic kidney disease (DKD) and suggests that fibroblast growth factor-23 and copeptin may help identify patients who would benefit from more aggressive management of cardiovascular risk factors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Xin Zhao, Jianbin Sun, Sixu Xin, Xiaomei Zhang
Summary: This study finds a correlation between the ratio of FT3 to FT4 and diabetic kidney disease in patients with type 2 diabetes mellitus. The retrospective analysis of 1729 hospitalized T2DM patients shows that those with a lower FT3/FT4 ratio have a higher incidence of DKD.
Article
Pharmacology & Pharmacy
Mei Jing, Yun Cen, Fangfang Gao, Ting Wang, Jinxin Jiang, Qianqian Jian, Liangmiao Wu, Baojian Guo, Fangcheng Luo, Gaoxiao Zhang, Ying Wang, Lipeng Xu, Zaijun Zhang, Yewei Sun, Yuqiang Wang
Summary: The study showed that TBN exhibited protective effects in both DKD animal models and nonhuman primate DKD models, reducing urinary albumin levels and improving renal histopathological changes, estimated glomerular filtration rate, and oxidative stress levels. TBN may improve mitochondrial function through activating the AMPK/PGC-1 alpha signaling pathway, thereby exerting its protective effects in DKD.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Urology & Nephrology
Matthew B. Palmer, Amin Abedini, Casey Jackson, Shira Blady, Shatakshee Chatterjee, Katie Marie Sullivan, Raymond R. Townsend, Jens Brodbeck, Salem Almaani, Anand Srivastava, Rupali Avasare, Michael J. Ross, Amy K. Mottl, Christos Argyropoulos, Jonathan Hogan, Katalin Susztak
Summary: This study analyzed the relationship between light and electron microscopic structural changes with clinical parameters and prognosis in diabetic kidney disease (DKD), identifying the crucial role of glomerular epithelial changes and kidney function decline. The study highlighted the association between fibrosis and kidney function, providing insights into the progression of DKD.
KIDNEY INTERNATIONAL REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Mohammed Al Za'abi, Badreldin H. Ali, Yousuf Al Suleimani, Sirin A. Adham, Haytham Ali, Priyadarsini Manoj, Mohammed Ashique, Abderrahim Nemmar
Summary: The study showed that metformin can effectively alleviate renal damage induced by adenine and STZ, especially when given together. This indicates that metformin may have an inhibitory effect on the progression of CKD in both diabetic and non-diabetic rats.
Article
Endocrinology & Metabolism
Yu Ho Lee, Jung-Woo Seo, Miji Kim, Donghyun Tae, Junhee Seok, Yang Gyun Kim, Sang-Ho Lee, Jin Sug Kim, Hyeon Seok Hwang, Kyung-Hwan Jeong, Ju-Young Moon
Summary: This study identified 30 DKD-specific mRNA candidates and found significant alterations in the urinary levels of 17 mRNAs in DKD patients compared to healthy controls. Four urinary mRNAs - LYZ, C3, FKBP5, and G6PC - reflected tubulointerstitial inflammation and fibrosis in kidney biopsy and could independently predict rapid progression to end-stage kidney disease.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Jianfang Shan, Zhengling Xu
Summary: This meta-analysis aimed to evaluate the efficacy and safety of multifactorial intensive treatment (MT) in patients with diabetic kidney disease (DKD). The findings indicated that MT was associated with a significant reduction in all-cause mortality and cardiovascular event disease rate. It also showed beneficial effects in delaying the progression of retinopathy, macroalbuminuria, and microalbuminuria. Additionally, MT did not increase the risk of adverse events. However, further large-scale RCTs are needed to confirm these results.
DIABETES OBESITY & METABOLISM
(2023)
Review
Medicine, General & Internal
Amninder Kaur, Gaurav Shekhar Sharma, Damodar R. Kumbala
Summary: Diabetes mellitus is the leading cause of chronic kidney disease and acute kidney injury, which can result in end-stage renal failure and higher morbidity and mortality. Understanding the risk factors and pathophysiological mechanisms of acute kidney injury in diabetic patients is crucial for intervention and prevention.
Article
Biochemistry & Molecular Biology
Aleksejs Fedulovs, Lilian Tzivian, Polina Zalizko, Santa Ivanova, Renate Bumane, Jana Janevica, Lelde Kruzmane, Eduards Krustins, Jelizaveta Sokolovska
Summary: Little research has been conducted on the link between diabetic kidney disease progression and diabetic gastroenteropathy in type 1 diabetes. In this study, a cross-sectional study was performed involving 100 T1D patients, and it was found that patients with progressive DKD had higher gastrointestinal symptom scores compared to those with stable DKD. The scores were negatively correlated with eGFR and positively correlated with albuminuria, HbA1c, and diabetes duration. The most commonly reported histopathological findings in the enteric mucosa were infiltration with eosinophils, lymphocytes, plasmacytes, the presence of lymphoid follicles, and lymphoid aggregates.
Article
Urology & Nephrology
Michael J. Ferkowicz, Ashish Verma, Daria Barwinska, Ricardo Melo Ferreira, Joel M. Henderson, Mary Kirkpatrick, Paolo S. Silva, Devin W. Steenkamp, Carrie L. Phillips, Sushrut S. Waikar, Timothy A. Sutton
Summary: The Kidney Precision Medicine Project aims to investigate human kidney biopsies to create a kidney tissue atlas, define disease subgroups, and identify targets for novel therapies. In this study, a kidney biopsy from a diabetic kidney disease patient revealed new cellular and molecular characteristics of the disease through three-dimensional immunofluorescence imaging and spatial transcriptomics.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Medical Laboratory Technology
Sushma Thimmaiah Kanakalakshmi, Shilna Muttickal Swaminathan, Pooja Basthi Mohan, Shankar Prasad Nagaraju, Mohan Bhojaraja, Sindhura Lakshmi Koulmane Laxminarayana
Summary: Diabetic kidney disease (DKD) is a common cause of renal failure in chronic kidney disease (CKD) patients. The limitations of current diagnostic markers call for the search of novel biomarkers. Microparticles, which play a role in cell-to-cell communication, show potential in early diagnosis and prognosis of DKD.
CLINICA CHIMICA ACTA
(2022)
Article
Urology & Nephrology
Alejandro Y. Meraz-Munoz, Nivethika Jeyakumar, Bin Luo, William Beaubien-Souligny, Rahul Chanchlani, Edward G. Clark, Ziv Harel, Abhijat Kitchlu, Javier A. Neyra, Michael Zappitelli, Glenn M. Chertow, Amit X. Garg, Ron Wald, Samuel A. Silver
Summary: Patients with a history of MI who survived AKI were less likely to receive prescriptions for cardiovascular drugs within 1 year of hospital discharge. This association was most pronounced in patients with stages 2 and 3 AKI.
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Medicine, General & Internal
Xingxing S. Cheng, Sai Liu, Jialin Han, Margaret R. Stedman, Michael Baiocchi, Jane C. Tan, Glenn M. Chertow, William F. Fearon
Summary: Testing for coronary heart disease (CHD) before kidney transplant is common, but its association with perioperative outcomes is unclear. This cohort study found that pretransplant CHD testing was not associated with a reduction in early posttransplant death or acute MI.
JAMA INTERNAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Jean-Claude Tardif, Jean Rouleau, Glenn M. Chertow, Ayman Al-Shurbaji, Vera Lisovskaja, Stephanie Gustavson, Yanli Zhao, Nadia Bouabdallaoui, Akshay S. Desai, Alexander Chernyavskiy, Maria Evsina, Bela Merkely, John J. V. McMurray, Marc A. Pfeffer
Summary: The PRIORITIZE-HF study, which aimed to evaluate the benefits and risks of using SZC to intensify RAAS inhibitor therapy in patients with heart failure and reduced ejection fraction (HFrEF), was prematurely terminated due to challenges related to the COVID-19 pandemic. The study did not demonstrate a statistically significant increase in the intensity of RAAS inhibitor therapies with SZC compared to placebo.
Article
Cardiac & Cardiovascular Systems
Anezi Uzendu, Kevin Kennedy, Glenn Chertow, Amit P. Amin, Jay S. Giri, Jennifer A. Rymer, Sripal Bangalore, Kimberly Lavin, Cornelia Anderson, John A. Spertus
Summary: This study aimed to compare the accuracy and implications of different GFR equations in predicting AKI after PCI. The results showed that for Black patients, risk models without a race term were more accurate than models with a race term. This has important implications for reducing disparities and benchmarking.
JACC-CARDIOVASCULAR INTERVENTIONS
(2023)
Article
Cardiac & Cardiovascular Systems
Anezi Uzendu, Kevin Kennedy, Glenn Chertow, Amit P. Amin, Jay S. Giri, Jennifer A. Rymer, Sripal Bangalore, Kimberly Lavin, Cornelia Anderson, Tracy Y. Wang, Jeptha P. Curtis, John A. Spertus
Summary: This study aimed to update the risk model for acute kidney injury (AKI) to improve its prediction after percutaneous coronary intervention (PCI). Through the use of a large registry database, the researchers successfully built a model with 13 variables and validated its calibration and discrimination in a separate cohort.
JACC-CARDIOVASCULAR INTERVENTIONS
(2023)
Article
Urology & Nephrology
Cynthia Delgado, Neil R. Powe, Glenn M. Chertow, Barbara Grimes, Kirsten L. Johansen
Summary: Among patients receiving dialysis, serum creatinine was higher in Black, Asian, and Hispanic patients than in non-Hispanic White patients. Differences in ICW did not explain the differences in serum creatinine concentration across race groups.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Urology & Nephrology
Robert A. Fletcher, Niels Jongs, Glenn M. Chertow, John J. V. Mcmurray, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Patrick Rockenschaub, Peter Rossing, Ricardo Correa-Rotter, Robert D. Toto, Muthiah Vaduganathan, David C. Wheeler, Hiddo J. L. Heerspink, Brendon L. Neuen
Summary: This study analyzed the effect of SGLT2 inhibitors on the discontinuation of RAS blockade and found that patients receiving SGLT2 inhibitors had a lower risk of discontinuing RAS blockade. This effect was particularly pronounced in patients with a high baseline urinary albumin-to-creatinine ratio.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Letter
Medicine, General & Internal
Vikram Fielding-Singh, Matthew W. Vanneman, Arden M. Morris, Glenn M. Chertow, Eugene Lin
Summary: This cohort study examines the relationship between patient characteristics and the time interval between hemodialysis and surgery in end-stage kidney disease patients.
Article
Medicine, General & Internal
Meri R. J. Varkila, Maria E. Montez-Rath, Joshua A. Salomon, Xue Yu, Geoffrey A. Block, Douglas K. Owens, Glenn M. Chertow, Julie Parsonnet, Shuchi Anand
Summary: The widespread use of at-home COVID-19 tests affects the determination of community COVID-19 incidence. A study found that wastewater metrics were associated with high case and hospitalization rates in the first quarter of 2022, but the association weakened in subsequent quarters, possibly due to underreporting, reduced testing, and the effect of vaccines and treatments. This study suggests using wastewater metrics to improve the assessment of community infection prevalence when conventional surveillance data is unreliable.
Article
Urology & Nephrology
Patrick S. Parfrey, Steven K. Burke, Glenn M. Chertow, Kai-Uwe Eckardt, Alan G. Jardine, Eldrin F. Lewis, Wenli Luo, Kunihiro Matsushita, Peter A. McCullough, Todd Minga, Wolfgang C. Winkelmayer
Summary: In the PRO2TECT trials, vadadustat was found to be comparable to darbepoetin alfa in terms of hematologic efficacy but not in major adverse cardiovascular events (MACE) in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Regional differences were observed in the rates of MACE, with higher rates in Europe for both vadadustat and darbepoetin alfa groups.
Meeting Abstract
Transplantation
Zhiyan Zhang, Hiddo Lambers Ileerspink, Glenn Chertow, Ricardo Correa-Rotter, Antonio Gasparrini, Niels Jong, Anna Maria Langkilde, Malcolm Mistry, John Mcmurray, Peter Rossing, Robert Toto, Priya Vart, Dorothea Misch, David C. Wheeler, Ben Caplin
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Meeting Abstract
Medicine, Research & Experimental
Halimat Afolabi, Bing Zhang, Michelle O'Shaughnessy, Glenn Chertow, Richard Lafayette, Vivek Charu
LABORATORY INVESTIGATION
(2023)
Article
Urology & Nephrology
Rajiv Agarwal, Sanjeev Anand, Kai-Uwe Eckardt, Wenli Luo, Patrick S. Parfrey, Mark J. Sarnak, Christine M. Solinsky, Dennis L. Vargo, Wolfgang C. Winkelmayer, Glenn M. Chertow
Summary: Anemia is common in chronic kidney disease (CKD) and has negative impacts on quality of life and cardiovascular outcomes. Current standard of care for anemia in CKD requires chronic injections, making it less accessible to certain patients. Safety concerns have also been raised regarding the use of erythropoiesis-stimulating agents. The orally active vadadustat may offer advantages over these agents by activating endogenous erythropoietin production.
AMERICAN JOURNAL OF NEPHROLOGY
(2023)
Meeting Abstract
Surgery
M. Stedman, P. Ahearn, C. K. Liu, G. M. Chertow, J. C. Tan
AMERICAN JOURNAL OF TRANSPLANTATION
(2023)
Article
Surgery
Thomas G. Peters, John J. Fung, Janet Radcliffe-Richards, Sally Satel, Alvin E. Roth, Frank McCormick, Martha Gershun, Arthur J. Matas, John P. Roberts, Josh Morrison, Glenn M. Chertow, Laurie D. Lee, Philip J. Held, Akinlolu Ojo
Summary: Living donor renal transplantation is considered the best treatment for permanent loss of kidney function, but it has not grown in the United States for over 20 years. A virtual symposium was held to address this issue, emphasizing the ethical principles and limitations of altruism as the sole motivation for donation. The potential of donor incentives to save lives and save taxpayer money was examined, with survey data showing support for donor compensation. The importance of removing barriers in donor evaluation, expanding living donor chains, ensuring the safety of live kidney donation, and relieving donors of financial burden was emphasized.
PROGRESS IN TRANSPLANTATION
(2023)